Neurosteroid withdrawal model of perimenstrual catamenial epilepsy

Doodipala S. Reddy, Hee Yong Kim, Michael A Rogawski

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Purpose: Perimenstrual catamenial epilepsy, the increase in seizure frequency that some women with epilepsy experience near the time of menstruation, may in part be related to withdrawal of the progesterone metabolite allopregnanolone, an endogenous anticonvulsant neurosteroid that is a potent positive allosteric γ-aminobutyric acidA (GABAA) receptor modulator. The objective of this study was to develop an animal model of perimenstrual catamenial epilepsy for use in evaluating drug-treatment strategies. Methods: A state of prolonged high serum progesterone (pseudopregnancy) was induced in 26-day-old female rats by sequential injection of pregnant mares' serum gonadotropin and human chorionic gonadotropin, Neurosteroid withdrawal was induced by treatment with finasteride (100 mg/kg, i.p.), a 5α-reductase inhibitor that blocks the conversion of progesterone to allopregnanolone. Plasma progesterone and allopregnanolone levels were measured by gas chromatography/ electron capture negative chemical ionization mass spectrometry. Seizure susceptibility was evaluated with the convulsant pentylenetetrazol (PTZ). Results: Plasma allopregnanolone levels were markedly increased during pseudopregnancy (peak level, 55,1 vs. control diestrous level, 9.3 ng/mL) and were reduced by 86% 24 h after finasteride treatment (6.4 ng/mL), Progesterone levels were unaffected by finasteride, After finasteride-induced withdrawal, rats showed increased susceptibility to PTZ seizures. There was a significant increase in the number of animals exhibiting clonic seizures when challenged with subcutaneous PTZ (60 mg/kg) compared with control pseudopregnant animals not undergoing withdrawal and nonpseudopregnant diestrous females. The CD50 (50% convulsant dose) was 46 mg/kg, compared with 73 mg/kg in nonwithdrawn pseudopregnant animals and 60 mg/kg in diestrous controls. The threshold doses for induction of various seizure signs, measured by constant intravenous infusion of PTZ, were reduced by 30-35% in neurosteroid-withdrawing animals compared with control diestrous females. No change in threshold was observed in pseudopregnant rats treated from days 7 to 11 with finasteride, demonstrating that high levels of progesterone alone do not alter seizure reactivity. Conclusions: Neurosteroid withdrawal in pseudopregnant rats results in enhanced seizure susceptibility, providing an animal model of perimenstrual catamenial epilepsy that can be used for the evaluation of new therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)328-336
Number of pages9
JournalEpilepsia
Volume42
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Menstruation
Finasteride
Neurotransmitter Agents
Epilepsy
Seizures
Pregnanolone
Progesterone
Pentylenetetrazole
Pseudopregnancy
Convulsants
Animal Models
Equine Gonadotropins
Chorionic Gonadotropin
GABA-A Receptors
Therapeutics
Intravenous Infusions
Gas Chromatography
Anticonvulsants
Mass Spectrometry
Oxidoreductases

Keywords

  • Allopregnanolone
  • Catamenial epilepsy
  • GABA receptor
  • Neurosteroid
  • Progesterone

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. / Reddy, Doodipala S.; Kim, Hee Yong; Rogawski, Michael A.

In: Epilepsia, Vol. 42, No. 3, 2001, p. 328-336.

Research output: Contribution to journalArticle

Reddy, Doodipala S. ; Kim, Hee Yong ; Rogawski, Michael A. / Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. In: Epilepsia. 2001 ; Vol. 42, No. 3. pp. 328-336.
@article{2c69bb01c7af428bb3ebba20b98c0fbc,
title = "Neurosteroid withdrawal model of perimenstrual catamenial epilepsy",
abstract = "Purpose: Perimenstrual catamenial epilepsy, the increase in seizure frequency that some women with epilepsy experience near the time of menstruation, may in part be related to withdrawal of the progesterone metabolite allopregnanolone, an endogenous anticonvulsant neurosteroid that is a potent positive allosteric γ-aminobutyric acidA (GABAA) receptor modulator. The objective of this study was to develop an animal model of perimenstrual catamenial epilepsy for use in evaluating drug-treatment strategies. Methods: A state of prolonged high serum progesterone (pseudopregnancy) was induced in 26-day-old female rats by sequential injection of pregnant mares' serum gonadotropin and human chorionic gonadotropin, Neurosteroid withdrawal was induced by treatment with finasteride (100 mg/kg, i.p.), a 5α-reductase inhibitor that blocks the conversion of progesterone to allopregnanolone. Plasma progesterone and allopregnanolone levels were measured by gas chromatography/ electron capture negative chemical ionization mass spectrometry. Seizure susceptibility was evaluated with the convulsant pentylenetetrazol (PTZ). Results: Plasma allopregnanolone levels were markedly increased during pseudopregnancy (peak level, 55,1 vs. control diestrous level, 9.3 ng/mL) and were reduced by 86{\%} 24 h after finasteride treatment (6.4 ng/mL), Progesterone levels were unaffected by finasteride, After finasteride-induced withdrawal, rats showed increased susceptibility to PTZ seizures. There was a significant increase in the number of animals exhibiting clonic seizures when challenged with subcutaneous PTZ (60 mg/kg) compared with control pseudopregnant animals not undergoing withdrawal and nonpseudopregnant diestrous females. The CD50 (50{\%} convulsant dose) was 46 mg/kg, compared with 73 mg/kg in nonwithdrawn pseudopregnant animals and 60 mg/kg in diestrous controls. The threshold doses for induction of various seizure signs, measured by constant intravenous infusion of PTZ, were reduced by 30-35{\%} in neurosteroid-withdrawing animals compared with control diestrous females. No change in threshold was observed in pseudopregnant rats treated from days 7 to 11 with finasteride, demonstrating that high levels of progesterone alone do not alter seizure reactivity. Conclusions: Neurosteroid withdrawal in pseudopregnant rats results in enhanced seizure susceptibility, providing an animal model of perimenstrual catamenial epilepsy that can be used for the evaluation of new therapeutic approaches.",
keywords = "Allopregnanolone, Catamenial epilepsy, GABA receptor, Neurosteroid, Progesterone",
author = "Reddy, {Doodipala S.} and Kim, {Hee Yong} and Rogawski, {Michael A}",
year = "2001",
doi = "10.1046/j.1528-1157.2001.10100.x",
language = "English (US)",
volume = "42",
pages = "328--336",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Neurosteroid withdrawal model of perimenstrual catamenial epilepsy

AU - Reddy, Doodipala S.

AU - Kim, Hee Yong

AU - Rogawski, Michael A

PY - 2001

Y1 - 2001

N2 - Purpose: Perimenstrual catamenial epilepsy, the increase in seizure frequency that some women with epilepsy experience near the time of menstruation, may in part be related to withdrawal of the progesterone metabolite allopregnanolone, an endogenous anticonvulsant neurosteroid that is a potent positive allosteric γ-aminobutyric acidA (GABAA) receptor modulator. The objective of this study was to develop an animal model of perimenstrual catamenial epilepsy for use in evaluating drug-treatment strategies. Methods: A state of prolonged high serum progesterone (pseudopregnancy) was induced in 26-day-old female rats by sequential injection of pregnant mares' serum gonadotropin and human chorionic gonadotropin, Neurosteroid withdrawal was induced by treatment with finasteride (100 mg/kg, i.p.), a 5α-reductase inhibitor that blocks the conversion of progesterone to allopregnanolone. Plasma progesterone and allopregnanolone levels were measured by gas chromatography/ electron capture negative chemical ionization mass spectrometry. Seizure susceptibility was evaluated with the convulsant pentylenetetrazol (PTZ). Results: Plasma allopregnanolone levels were markedly increased during pseudopregnancy (peak level, 55,1 vs. control diestrous level, 9.3 ng/mL) and were reduced by 86% 24 h after finasteride treatment (6.4 ng/mL), Progesterone levels were unaffected by finasteride, After finasteride-induced withdrawal, rats showed increased susceptibility to PTZ seizures. There was a significant increase in the number of animals exhibiting clonic seizures when challenged with subcutaneous PTZ (60 mg/kg) compared with control pseudopregnant animals not undergoing withdrawal and nonpseudopregnant diestrous females. The CD50 (50% convulsant dose) was 46 mg/kg, compared with 73 mg/kg in nonwithdrawn pseudopregnant animals and 60 mg/kg in diestrous controls. The threshold doses for induction of various seizure signs, measured by constant intravenous infusion of PTZ, were reduced by 30-35% in neurosteroid-withdrawing animals compared with control diestrous females. No change in threshold was observed in pseudopregnant rats treated from days 7 to 11 with finasteride, demonstrating that high levels of progesterone alone do not alter seizure reactivity. Conclusions: Neurosteroid withdrawal in pseudopregnant rats results in enhanced seizure susceptibility, providing an animal model of perimenstrual catamenial epilepsy that can be used for the evaluation of new therapeutic approaches.

AB - Purpose: Perimenstrual catamenial epilepsy, the increase in seizure frequency that some women with epilepsy experience near the time of menstruation, may in part be related to withdrawal of the progesterone metabolite allopregnanolone, an endogenous anticonvulsant neurosteroid that is a potent positive allosteric γ-aminobutyric acidA (GABAA) receptor modulator. The objective of this study was to develop an animal model of perimenstrual catamenial epilepsy for use in evaluating drug-treatment strategies. Methods: A state of prolonged high serum progesterone (pseudopregnancy) was induced in 26-day-old female rats by sequential injection of pregnant mares' serum gonadotropin and human chorionic gonadotropin, Neurosteroid withdrawal was induced by treatment with finasteride (100 mg/kg, i.p.), a 5α-reductase inhibitor that blocks the conversion of progesterone to allopregnanolone. Plasma progesterone and allopregnanolone levels were measured by gas chromatography/ electron capture negative chemical ionization mass spectrometry. Seizure susceptibility was evaluated with the convulsant pentylenetetrazol (PTZ). Results: Plasma allopregnanolone levels were markedly increased during pseudopregnancy (peak level, 55,1 vs. control diestrous level, 9.3 ng/mL) and were reduced by 86% 24 h after finasteride treatment (6.4 ng/mL), Progesterone levels were unaffected by finasteride, After finasteride-induced withdrawal, rats showed increased susceptibility to PTZ seizures. There was a significant increase in the number of animals exhibiting clonic seizures when challenged with subcutaneous PTZ (60 mg/kg) compared with control pseudopregnant animals not undergoing withdrawal and nonpseudopregnant diestrous females. The CD50 (50% convulsant dose) was 46 mg/kg, compared with 73 mg/kg in nonwithdrawn pseudopregnant animals and 60 mg/kg in diestrous controls. The threshold doses for induction of various seizure signs, measured by constant intravenous infusion of PTZ, were reduced by 30-35% in neurosteroid-withdrawing animals compared with control diestrous females. No change in threshold was observed in pseudopregnant rats treated from days 7 to 11 with finasteride, demonstrating that high levels of progesterone alone do not alter seizure reactivity. Conclusions: Neurosteroid withdrawal in pseudopregnant rats results in enhanced seizure susceptibility, providing an animal model of perimenstrual catamenial epilepsy that can be used for the evaluation of new therapeutic approaches.

KW - Allopregnanolone

KW - Catamenial epilepsy

KW - GABA receptor

KW - Neurosteroid

KW - Progesterone

UR - http://www.scopus.com/inward/record.url?scp=0035057345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035057345&partnerID=8YFLogxK

U2 - 10.1046/j.1528-1157.2001.10100.x

DO - 10.1046/j.1528-1157.2001.10100.x

M3 - Article

C2 - 11442149

AN - SCOPUS:0035057345

VL - 42

SP - 328

EP - 336

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 3

ER -